Orchard Therapeutics plc Initial Public Offering

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $225 million initial public offering by Orchard Therapeutics plc of 16,103,572 American Depositary Shares, each representing one ordinary share. The ADSs are listed on the NASDAQ Global Select Market under the symbol “ORTX.”

Headquartered in London, United Kingdom, Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Orchard’s advanced portfolio of autologous ex vivo gene therapies targets serious and life-threatening rare diseases, initially primary immune deficiencies, neurometabolic disorders and hemoglobinopathies.

The Davis Polk capital markets team included partner Deanna L. Kirkpatrick and associates Andrew J. Terjesen, Rahim Manji and Jae Maeng. Partner David R. Bauer and associate Tilak Koilvaram provided intellectual property and technology advice. The tax team included partners Po Sit and Jonathan Cooklin and associate Gil Savir. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and London offices.